*Applications will be reviewed on a rolling-basis, and this opportunity will remain open until filled.
A research opportunity is currently available in the Division of Cellular and Gene Therapies, in the Office of Tissues and Advanced Therapies (OTAT) at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
The research is focused on understanding the emerging vector-borne disease pathogenesis such as tick-borne diseases. The project will involve emerging tick-borne disease pathogens and tick biology. The study will focus on understanding what makes ticks the most prolific disease vector for humans, livestock and companion animals. The participant will work with Ixodes scapularis ticks (deer ticks) and I. scapularis-borne pathogens. The participant will use advanced tools such as next-generation sequencing and oligo-paint imaging assays.
Anticipated Appointment Start Date: As soon as a qualified candidate is identified; start date is flexible
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2021-0044) in your email.